Erasca and Eli Lilly and Company have signed a clinical trial collaboration and supply agreement (CTCSA) to evaluate ERAS-601 in combination with Eli Lilly’s anti-EGFR antibody cetuximab (ERBITUX).
A potential, selective oral inhibitor of SHP2, ERAS-601 acts as convergent node for receptor tyrosine kinase (RTK) signalling.
It is currently being evaluated alone or in combination with approved and investigational agents across many clinical trials that cover multiple tumour types.
The ongoing Phase I/Ib FLAGSHP-1 has been designed to evaluate Erasca’s ERAS-601 in various combinations, including with Eli Lilly’s cetuximab, to treat triple wildtype (KRAS/NRAS/BRAF wildtype) metastatic colorectal cancer (CRC) and human papillomavirus (HPV)-negative advanced head and neck squamous cell carcinoma (HNSCC).
Under the collaboration, Lilly will be responsible for the supply of cetuximab for the trial at no cost, while Erasca will provide funding for this clinical proof of concept trial.
Erasca chairman, CEO, and co-founder Jonathan Lim said: “We are pleased to enter another clinical trial collaboration with Lilly to explore cetuximab in combination with ERAS-601, our SHP2 inhibitor, in EGFR-driven cancers that are highly dependent on RAS/MAPK signalling.
“Dual inhibition of EGFR and SHP2, a convergent RTK signalling node, has the potential to broaden and deepen responses relative to cetuximab monotherapy and delay onset of resistance in cancers like triple wildtype metastatic CRC and HPV-negative advanced HNSCC.”
In March this year, the company signed a CTCSA with Eli Lilly to evaluate its ERAS-007, an oral ERK1/2 inhibitor, in combination with Eli Lilly’s cetuximab in a Phase Ib/II HERKULES-3 trial.
In September last year, Erasca signed CTCSA with Pfizer to evaluate ERAS-007 in combination with the latter’s BRAF inhibitor encorafenib (BRAFTOVI) in Phase Ib/II HERKULES-3 trial.